share_log

BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress; Co. Reports 'Trial did not meet the co-primary efficacy endpoints; no new safet

BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress; Co. Reports 'Trial did not meet the co-primary efficacy endpoints; no new safet

BEY基因提供扎努布鲁替尼治疗新冠肺炎相关肺窘迫患者的第二阶段临床试验的最新情况；Co.Reports公司的试验没有达到共同的主要疗效终点；没有新的SAFET
Benzinga Real-time News ·  2021/04/08 19:08

BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress; Co. Reports 'Trial did not meet the co-primary efficacy endpoints; no new safety signals identified'

BEY基因提供了扎努布鲁替尼治疗新冠肺炎相关肺窘迫患者的第二阶段临床试验的最新情况；公司报道说，试验没有达到共同的主要疗效终点；没有发现新的安全信号。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发